BCL2L11 and osteosarcoma: These similar responses suggest that CtBP1 may not participate in the aberrant expression of CDH1, BAX, BIM, and PTEN observed in osteosarcoma CSCs, as greater phenotype effects would have been expected following knockdown of CtBP1 or NSM00158 treatment than following FOXM1 knockdown or RCM1 treatment.